GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer (NCT07489287) | Clinical Trial Compass
RecruitingPhase 1
GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer
United States18 participantsStarted 2026-07-15
Plain-language summary
This phase 1 study evaluates the safety, efficacy, and biological activity of GB-5267 in patients with platinum-resistant ovarian cancer.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Progression of disease within 6 months of last platinum-based chemotherapy, OR
. Patients who have an intolerance for further platinum-based therapy.
. Absolute neutrophil count (ANC) \> 1,000/mm3
. Platelet count \> 50,000/mm3
. Hemoglobin \> 8.5 g/dL
. Total bilirubin \< 1.5 x ULN, except in subjects with Gilbert's Syndrome who must have a total bilirubin \< 3 x ULN
. Aspartate and alanine aminotransferase (AST and ALT) \< 3 x ULN; \< 5 x ULN if there is liver involvement by the tumor.
. A pretreatment biopsy must be obtained following completion of screening procedures and at least 7 days prior to the cell infusion.
Exclusion criteria
. Recent significant bleeding, defined as a history of Grade ≥2 hemorrhage within 30 days before Screening.
. Coagulation parameters (assessed at Screening):
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Maximum Tolerated Dose (MTD) - Cohort A
Timeframe: 28 days from GB-5267 cell infusion
2
Number of DLTs in combined IV and IP infusions of GB-5267 - Cohort B
Timeframe: Day 0 through day 7 after GB-5267 infusion
. Anticoagulant use: Current use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes is excluded. Prophylactic anticoagulation (e.g., low-molecular-weight heparin \[LMWH\] 40 mg/day) or use of anticoagulants for venous access device patency is permitted if the participant has been on a stable dose for ≥4 weeks without bleeding complications.
. History of Class III or IV congestive heart failure, non-ischemic cardiomyopathy, unstable or poorly controlled angina, or peripheral arterial disease event within 6 months prior to enrollment.
. Echocardiogram or multigated acquisition (MUGA) scan with left ventricular ejection fraction (LVEF) \<40%.
. Previous myocardial infarction within 1 year prior to Screening.
. Clinically significant arrhythmia (e.g., second- or third-degree AV block, paroxysmal atrial fibrillation requiring active treatment, or prior pacemaker/defibrillator placement).